Curaleaf International Expands Medical Cannabis Offerings to Australia

Curaleaf International Expands into the Australian Market

Curaleaf International, a subsidiary of Curaleaf Holdings, Inc. (TSX:CURA), has announced its entry into the Australian market with an exciting range of branded medical cannabis products. This marks a significant milestone for the company as Australia emerges as one of the fastest-growing markets for medical cannabis globally.

By introducing its products in Australia, Curaleaf reinforces its dedication to collaborating with local entities, ensuring clinical integrity, and prioritizing patient care. The initial launch includes four distinct strains of cannabis flower, which will be distributed in partnership with Canngea, a licensed Australian manufacturer and wholesaler well-versed in medical cannabis distribution. This collaboration aligns with Curaleaf's goal of providing high-quality cannabis products and services to its clientele.

In the upcoming months, medical practitioners and patients across Australia can anticipate a wider selection of innovative solutions. Curaleaf aims to introduce precision-dosed inhalation products and various strains that have been highly regarded in markets like the UK and Germany. As they set their sights on improving patient access to effective cannabis medicines, Curaleaf is poised to meet growing demand and enhance the standards of medical cannabis care in Australia.

Juan Martinez, who leads Curaleaf International, expressed the importance of this launch, stating, "We see entering the Australian market as not just an expansion, but a vital step in our global initiative to make quality, evidence-based cannabis accessible. Our commitment is to support Australian patients and healthcare professionals with reliable and consistent products, backed by one of the most advanced supply chains in the industry."

Boris Jordan, the Chairman and CEO of Curaleaf, emphasized the promising future of the Australian market, noting its expected growth to surpass $1 billion in annual sales by next year. "This launch is an important move in our strategy to solidify our leadership position globally in the cannabis sector. We are thrilled to introduce our established portfolio and bring forth additional innovations as we progress," he said.

Curaleaf International prides itself on shaping the future of cannabis through rigorous research and commitment to product excellence. With a robust presence at every level of the supply chain, the company integrates cutting-edge cultivation, extraction, and production techniques, ensuring the delivery of safe, legal, and high-quality cannabis products.

Their diverse operational network encompasses a multitude of facilities, including a clinic, pharmacy, and laboratory in the UK, alongside cultivation and EU-GMP processing facilities in Portugal and Spain. Additionally, Curaleaf operates as a wholesaler and distributor in Germany and Poland, ensuring a comprehensive reach throughout Europe, Canada, and Australasia.

Through its dedication to quality and expertise, Curaleaf International aims to remain at the forefront of the rapidly evolving cannabis industry. As the company continues to expand, it remains committed to delivering premium products that meet the needs of patients and healthcare providers alike. The expansion into Australia is not merely a business venture but a transformative step toward enhancing healthcare options via medical cannabis, showcasing the company's innovation and market adaptability.

For more information, please contact Beth Sweet-Escott, Head of Communications at Curaleaf International, via email.